James R Kiefer
Overview
Explore the profile of James R Kiefer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Braun M, Ashkenazi A, Beveridge R, Castanedo G, Wallweber H, Beresini M, et al.
J Med Chem
. 2024 May;
67(11):8708-8729.
PMID: 38748820
The lack of selective and safe in vivo IRE1α tool molecules has limited the evaluation of IRE1α as a viable target to treat multiple myeloma. Focus on improving the physicochemical...
2.
Hanan E, Braun M, Heald R, MacLeod C, Chan C, Clausen S, et al.
J Med Chem
. 2022 Dec;
65(24):16589-16621.
PMID: 36455032
Small molecule inhibitors that target the phosphatidylinositol 3-kinase (PI3K) signaling pathway have received significant interest for the treatment of cancers. The class I isoform PI3Kα is most commonly associated with...
3.
Ogasawara A, Kiefer J, Gill H, Chiang E, Sriraman S, Ferl G, et al.
Eur J Nucl Med Mol Imaging
. 2022 Nov;
50(2):631.
PMID: 36427067
No abstract available.
4.
Sriraman S, Davies C, Gill H, Kiefer J, Yin J, Ogasawara A, et al.
Eur J Nucl Med Mol Imaging
. 2022 Nov;
50(3):679-691.
PMID: 36346438
Purpose: Cancer immunotherapies (CITs) have revolutionized the treatment of certain cancers, but many patients fail to respond or relapse from current therapies, prompting the need for new CIT agents. CD8...
5.
Ogasawara A, Kiefer J, Gill H, Chiang E, Sriraman S, Ferl G, et al.
Eur J Nucl Med Mol Imaging
. 2022 Oct;
50(2):287-301.
PMID: 36271158
Background: ZED8 is a novel monovalent antibody labeled with zirconium-89 for the molecular imaging of CD8. This work describes nonclinical studies performed in part to provide rationale for and to...
6.
Muller S, Ackloo S, Al Chawaf A, Al-Lazikani B, Antolin A, Baell J, et al.
RSC Med Chem
. 2022 Feb;
13(1):13-21.
PMID: 35211674
Twenty years after the publication of the first draft of the human genome, our knowledge of the human proteome is still fragmented. The challenge of translating the wealth of new...
7.
Kakiuchi-Kiyota S, Ross T, Wallweber H, Kiefer J, Schutten M, Adedeji A, et al.
Leukemia
. 2022 Jan;
36(4):1006-1014.
PMID: 35001074
Despite the recent progress, multiple myeloma (MM) is still essentially incurable and there is a need for additional effective treatments with good tolerability. RO7297089 is a novel bispecific BCMA/CD16A-directed innate...
8.
Phillips G, Guo J, Kiefer J, Proctor W, Bumbaca Yadav D, Dybdal N, et al.
Breast Cancer Res Treat
. 2021 Oct;
191(2):303-317.
PMID: 34708303
Purpose: Assessment of non-clinical safety signals relies on understanding species selectivity of antibodies. This is particularly important with antibody-drug conjugates, where it is key to determine target-dependent versus target-independent toxicity....
9.
Zbieg J, Liang J, Li J, Blake R, Chang J, Friedman L, et al.
Bioorg Med Chem Lett
. 2021 Aug;
50:128335.
PMID: 34425201
Fulvestrant is an FDA-approved drug with a dual mechanism of action (MOA), acting as a full antagonist and degrader of the estrogen receptor protein. A significant limitation of fulvestrant is...
10.
Liang J, Zbieg J, Blake R, Chang J, Daly S, DiPasquale A, et al.
J Med Chem
. 2021 Jul;
64(16):11841-11856.
PMID: 34251202
Breast cancer remains a leading cause of cancer death in women, representing a significant unmet medical need. Here, we disclose our discovery efforts culminating in a clinical candidate, (GDC-9545 or...